HomeInsightsPE

Indoco Remedies Ltd P/E Ratio

Indoco Remedies Ltd P/E Ratio

download
stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

0.8 K

stocks traded

Last Updated time: 25 Jul 11:49 AM

Image

Indoco Remedies Ltd

NSE: INDOCO

PE

42.9

Last updated : 25 Jul 11:49 AM

Key Highlights

    The P/E Ratio of Indoco Remedies Ltd is 42.9 as of 25 Jul 11:49 AM .a1#The P/E Ratio of Indoco Remedies Ltd changed from 79.9 on March 2019 to 21.1 on March 2023 . This represents a CAGR of -28.31% over 4 years. a1#The Latest Trading Price of Indoco Remedies Ltd is ₹ 325.9 as of 25 Jul 11:43 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Indoco Remedies Ltd changed from ₹ 1867 crore on March 2019 to ₹ 2999 crore on March 2023 . This represents a CAGR of 9.94% over 5 years. a1#The Revenue of Indoco Remedies Ltd changed from ₹ 409.35 crore to ₹ 432.52 crore over 9 quarters. This represents a CAGR of 2.48% a1#The EBITDA of Indoco Remedies Ltd changed from ₹ 72.58 crore to ₹ 48.8 crore over 9 quarters. This represents a CAGR of -16.17% a1#The Net Pr of Indoco Remedies Ltd changed from ₹ 38.57 crore to ₹ 1.82 crore over 9 quarters. This represents a CAGR of -74.26% a1#The Dividend Payout of Indoco Remedies Ltd changed from -97.34 % on March 2019 to 14.67 % on March 2023 . This represents a CAGR of NaN% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Indoco Remedies Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Indoco Remedies Ltd

Period
Mar '190
Mar '2079.9
Mar '2128.6
Mar '2222.4
Mar '2321.1

Company Fundamentals for Indoco Remedies Ltd

Market Cap

2,964 Cr

EPS

7.5

P/E Ratio (TTM) *

42.9

P/B Ratio (TTM) *

2.7

Day’s High

325.9

Day’s Low

318.5

DTE *

0.6

ROE *

8.9

52 Week High

416.95

52 Week Low

286.5

ROCE *

9.7

* All values are consolidated

Last Updated time: 25 Jul 11:49 AM

* All values are consolidated

Last Updated time: 25 Jul 11:49 AM

Image

Indoco Remedies Ltd

NSE: INDOCO

PRICE

325.9

4.35 (1.35%)

stock direction

Last updated : 25 Jul 11:43

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Indoco Remedies Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value of Indoco Remedies Ltd

Market Value

2,964

Asset Value

833

2.6 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Indoco Remedies Ltd422,964
Sun Pharmaceuticals Industries Ltd38388,632
Cipla Ltd28121,443
Divis Laboratories Ltd75120,718
Zydus Lifesciences Ltd30118,680
Dr Reddys Laboratories Ltd20113,730

Key Valuation Metric of Indoco Remedies Ltd

Earnings

76 Cr

42.9 X

PE Ratio

Market Cap

₹2964Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

76 Cr

42.9 X

PE Ratio

Market Cap

₹2964Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Indoco Remedies Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Indoco Remedies Ltd

Period
Mar '191868
Mar '201929
Mar '212659
Mar '223470
Mar '233000

* All values are a in crore

×

Historical Revenue of Indoco Remedies Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Indoco Remedies Ltd

Period
Jun '22409
Sep '22433
Dec '22400
Mar '23429
Jun '23427
Sep '23486
Dec '23462
Mar '24472
Jun '24433

* All values are a in crore

×

Historical EBITDA of Indoco Remedies Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Indoco Remedies Ltd

Period
Jun '2273
Sep '2288
Dec '2262
Mar '2365
Jun '2362
Sep '2376
Dec '2357
Mar '2471
Jun '2449

* All values are a in crore

×

Historical Net Profit of Indoco Remedies Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Indoco Remedies Ltd

Period
Jun '2239
Sep '2250
Dec '2228
Mar '2326
Jun '2324
Sep '2335
Dec '2316
Mar '2422
Jun '242

* All values are a in crore

×

Historical Dividend Payout of Indoco Remedies Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Indoco Remedies Ltd

Period
Mar '19-97
Mar '2011
Mar '2115
Mar '2213
Mar '2315

* All values are a in %

About Indoco Remedies Ltd

About Indoco Remedies Ltd

    Indoco Remedies Limited, incorporated as a Public Limited Company in August 23, 1947 is a Mumbai-based pharmaceutical company that focuses on formulations, with some presence in contract manufacturing and research. The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 166 million Company, employs over 6000 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal. As per AC Nielsen ORG-MARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORG-MARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardio-vascular segments. Its entry into the lifestyle segment with a strong presence in the prescription segment would augur well for the higher- than-average industry growth. Currently, Indoco has four manufacturing facilities. Two are located in Mumbai and two in Goa, and an R&D centre in Mumbai. The solid dosage facility in Goa has been accredited by UK-Medicines and Healthcare Products Regulatory Agency (MHRA), and the sterile plant of Goa has been designed as per US Food and Drug Administration (FDA) norms. On the selling front, it has a marketing network of 1,248 medical representatives. In July 2014, the Company purchased the remaining shares of its subsidiary, Xtend Industrial Designers and Engineers Private Limited to make it a 100% subsidiary of the Company. In April 2015, the Company acquired from Piramal Enterprise Limited, their Clinical Research Division, located in Hyderabad. The division is equipped with a 98-bed facility, including a four-bed ICU, state-of-the-art analytical lab and capabilities of eCTD submission. It also has GCP certification from UK-MHRA and also has regulatory approvals from several bodies including USFDA. The acquisition would reduce the Company's dependability to outsource bio-equivalence studies. This will not only reduce cost but also ensure time-bound outcome of studies and add pace to the Company's existing R&D efforts. In December, 2015, the Company incorporated Indoco Remedies Singapore Pte Limited, a 100% subsidiary. The subsidiary will be used for the expansion of the company's ambitious plans to extend its activities in the European and US markets. The company has the following 3 subsidiary companies as on 31 March 2016.i. Xtend Industrial Designers and Engineers Private Limited,ii. Indoco Pharmchem Limited,iii. Indoco Remedies Singapore Pte. Ltd. The cash outflow on account of Capital Expenditure (CAPEX) during FY2016 was Rs 97.7 crore, as compared to Rs 88.7 crore in the last year. The cash outflow on account of Capital Expenditure (CAPEX) during FY2017 was Rs 130.60 crore, as compared to Rs 97.70 crore in the last year. As on 31 March 2018,the company has 2 subsidiary companies under its fold. As there was no business activity, the Company during the year has applied to the Registrar of Companies for striking off the names of following Companies,i. Indoco Pharmchem Limited - 100% subsidiary,ii. Indoco Analytical Solutions LLP - Associate LLP. The cash outflow on account of Capital Expenditure (CAPEX) during FY2018 was Rs 139.4 crore, as compared to Rs 189.6 crore in the last year. During the year 2017-18, the Company (F&D) was granted two patents by the Indian Patent Office and one by United States Patents Office for formulation of Olopatadine, Gliclazide, and Brinzolamide respectively. The Company was also granted three patents by Indian Patents Office for manufacturing processes of three APIs, viz., Febuxostat, Rufinamide and Lacosamide. Indoco's R&D efforts received due recognition with the Best Process Patent Award for the year 2016-2017' forfive Indian patents granted related to Processforthe preparation of Tapentadol', Process for the preparation of Aminoindane compound', Process for preparation of Pyrazole derivatives', Preparation of phenylacetic acid derivative' and Preparation of Substituted 1H-imidazo[4,5-c] quinoline'. This award was presented at Indian Drug Manufacturers Association's 56th Annual Day celebrations held on 20 January 2018. As on March 31, 2019, the Company has one subsidiary viz Xtend Industrial Designers and Engineers Pvt. Ltd. (XIDEPL). As there was No Business Activity, the following subsidiary has been voluntarily wound up during the year under consideration. - 100% subsidiary- Indoco Remedies Singapore Pte Ltd.In order to expand its business in the European market, the Company has effective 09 April 2019 set up a 100% subsidiary in the Czech Republic. The cash outflow on account of Capital Expenditure (CAPEX) during FY2019 was Rs 96.95 crore, as compared to Rs 139.45 crore in the last year. As on March 31, 2020, the Company had two subsidiaries:i. Xtend Industrial Designers and Engineers Pvt. Ltd. (XIDEL),ii. Indoco Remedies Czech sro. During the year 2019-20, eight new products, five in Cardiac segment, two in Anti-diabetic segment and one in Dermatology segment, were launched. As on March 31, 2021, the Company had two subsidiaries, Xtend Industrial Designers and Engineers Pvt. Ltd. and Indoco Remedies Czech sro. As on March 31, 2022, the Company has 3 Subsidiary Companies, Xtend Industrial Designers and Engineers Private Limited, Indoco Remedies Czech SRO and Indoco Remedies UK Limited.

Indoco Remedies Ltd News Hub

News

Indoco Remedies to conduct board meeting

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 23 July 20...

Read more

11 Jul 202409:31

News

Indoco Remedies receives USFDA approval for Canagliflozin and Metformin Hydrochloride Tablets

Indoco Remedies announced the receipt of tentative approval from the USFDA for Abbreviated...

Read more

07 Jun 202408:40

News

Indoco Remedies gains after receiving USFDA nod for type 2 diabetes drug

Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellit...

Read more

06 Jun 202414:47

News

US FDA concludes audit of Indoco's Rabale facility & IAS division with zero observations

The inspection concluded with zero Form 483 observations. Aditi Panandikar, managing direc...

Read more

17 May 202409:21

News

Indoco Remedies' APIL Kilo Lab manufacturing unit completes USFDA audit

Indoco Remedies announced that United States Food and Drug Administration (USFDA) had insp...

Read more

17 May 202410:43

News

Board of Indoco Remedies recommends Final Dividend

Indoco Remedies announced that the Board of Directors of the Company at its meeting held o...

Read more

16 May 202417:51

Product Composition by Percentage (Revenue)

FAQs for PE of Indoco Remedies Ltd

What is Indoco Remedies Ltd current share price?

The current market price of Indoco Remedies Ltd as of July 25, 2024 is ₹325.90.

What is Indoco Remedies Ltd's market cap?

Indoco Remedies Ltd's market capitalisation stood at ₹2,964 Cr as of July 25, 2024

What are Indoco Remedies Ltd's total net assets?

According to Indoco Remedies Ltd's most recent financial filings, the company's net assets total ₹833.5 Cr.

Is Indoco Remedies Ltd making a profit or loss?

Indoco Remedies Ltd's net Profit as of July 25, 2024 is close to ₹76 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199